주식 시장 뉴스
최신 금융 뉴스 · 업데이트 7월 24, 2026
TJX Companies: 성장을 위한 준비된 소매 강자
TJX Companies: A Retail Powerhouse Poised for Growth
Despite TJX's 'treasure hunt' psychological moat, panelists express concerns about potential inventory supply tightening due to brands improving demand forecasting …
왜 KinderCare 학습 주식이 금요일에 하락했는가
Why KinderCare Learning Stock Flopped on Friday
Panelists disagree on the sustainability of KLC's pricing power and enrollment trends. While some see a 'temporary fix', others warn …
Poet Technologies, 오늘 급락 — 지금 주식을 매수해야 할까?
Poet Technologies Sank Today -- Is The Stock a Buy Right Now?
Panelists generally agree that POET Technologies is heavily reliant on the Lumilens deal for success, but they have significant concerns …
Alumis 주식 300% 이상 상승. 주요 헬스케어 투자자 매도 중
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
The panel consensus is that Omega Fund Management's sale of ALMS shares is likely a rebalancing act rather than a …
Kestra Medical 수익이 63% 증가했습니다. 한 기금이 351,000주식을 매도했습니다
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Panelists agree that Kestra Medical's cash burn rate is a significant concern, with the company having around 18-20 months of …
이 펀드의 라이온게이트 스튜디오에 대한 더 큰 투자에 대해 알아야 할 사항, 85% 주식 상승 중
What to Know About This Fund’s Bigger Bet on Lionsgate Studios Amid an 85% Stock Surge
The panel is divided on Lionsgate's future, with some seeing it as a potential takeover target due to its content …
이 '지루한' 주식이 지금 사기 좋은 이유
Why This "Boring" Stock Is a Strong Buy Right Now
The panel's net takeaway is that Coca-Cola's current valuation (24x forward P/E) leaves little room for margin compression, and its …
찰스 슈왑 주가가 금요일에 상승한 이유
Why Charles Schwab Stock Bumped Higher on Friday
Panelists are neutral on Schwab, citing rate sensitivity and structural risks, while acknowledging potential ROE improvement from deposit normalization.
이 기술주, 5년 동안 인내심 있는 투자자에게 수익을 창출했으며, 여전히 저렴합니다
This Tech Stock Has Printed Money for Patient Investors for 5 Years, and It's Still Cheap
Onto Innovation's growth prospects hinge on the successful ramp of the Dragonfly G5 platform and maintaining its large HBM backlog. …
이 여행주 38% 하락했으나, 펀드가 $24백만 규모로 포지션을 증가시킴
This Travel Stock Is Down 38%, but a Fund Just Increased Its Position by $24 Million
The panel generally expresses skepticism about TRIP's turnaround prospects, with concerns about the core hotel business's decay, lack of operating …
£20,000을 갚지 않아도 되었음: 부모들이 아동 양육비 오류로 피해
'They took £20,000 I didn't owe': Parents hit by child maintenance errors
The panel agrees that the Child Maintenance Service's (CMS) high appeal overturn rate and lack of transparency regarding the monetary …
예측: 이 주식은 2031년까지 두 배로 증가할 수 있습니다 ### TEXT ## ## 주요 포인트 엑셀릭시스의 주요 제품은 10년 말까지 성장을 이끌어갈 것입니다. 회사는 그 뒤를 이어받을 약물에 대한 승인을 받을 단계에 있습니다. 바이오테크는 여러 유망한 초기 단계 프로그램을 보유하고 있습니다. - 엑셀릭시스보다 더 좋은 10개 주식 › **엑셀릭시스**(NASDAQ: EXEL)는 지난 5년간 소유하기 좋은 주식이었으며, 주가가 101% 상승하여 **S&P 500**을 약간 앞섰습니다. 좋은 소식은 이 바이오테크 회
Prediction: This Stock Could Double By 2031
Panelists agreed that Exelixis' valuation hinges on the success of zanzalintinib, with significant risks around its late-stage trials and patent …